Lynn Million1, Andrea Hayes-Jordan2, Yueh-Yun Chi3, Sarah S Donaldson4, Suzanne Wolden5, Carol Morris6, Stephanie Terezakis7, Fran Laurie8, Karen Morano8, T J Fitzgerald9, Torunn I Yock10, David A Rodeberg11, James R Anderson12, Rose Anne Speights13, Jennifer O Black14, Cheryl Coffin15, Mary Beth McCarville13, Simon C Kao16, Douglas S Hawkins17, Sheri L Spunt4, R Lor Randall18. 1. Department of Radiation Oncology (LM, SSD) and Department of Pediatrics (SS), Stanford University, Stanford, California. Electronic address: lmillion@stanford.edu. 2. Department of Surgery, University of North Carolina, Chapel Hill, North Carolina. 3. Department of Biostatistics, University of Southern California, Los Angeles, California. 4. Department of Radiation Oncology (LM, SSD) and Department of Pediatrics (SS), Stanford University, Stanford, California. 5. Department of Radiation Oncology, Memorial Sloan Cancer Center, New York, New York. 6. Department of Orthopedic Surgery, Johns Hopkins University, Baltimore Maryland. 7. Department of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota. 8. Imaging and Radiation Oncology Core (IROC), Lincoln, Rhode Island. 9. Department of Radiation Oncology, University of Massachusetts, Worcester, Massachusetts. 10. Department of Radiation Oncology, Massachusetts General Hospital, Boston Massachusetts. 11. Department of Surgery, East Carolina University, Greenville, North Carolina. 12. MERCK Research Laboratories, North Wales, Pennsylvania. 13. St. Jude Children's Research Hospital, Memphis, Tennessee. 14. Department of Pathology, Children's Hospital Colorado, Aurora, Colorado. 15. Department of Pathology, Vanderbilt University, Nashville, Tennessee. 16. Department of Radiology, University of Iowa, Iowa City, Iowa. 17. Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington. 18. Department of Orthopedics, University of California Davis, Sacramento, California.
Abstract
PURPOSE: The ARST0332 trial for pediatric and young adults with nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) used risk-based treatment including primary resection with lower-than-standard radiation doses to optimize local control (LC) while minimizing long-term toxicity in those requiring radiation therapy (RT). RT for high-grade NRSTS was based on extent of resection (R0: negative margins, R1: microscopic margins, R2/U: gross disease/unresectable); those with >5 cm tumors received chemotherapy (CT; ifosfamide/doxorubicin). This analysis evaluates LC for patients assigned to RT and prognostic factors associated with local recurrence (LR). METHODS AND MATERIALS: Patients aged <30 years with high-grade NRSTS received RT (55.8 Gy) for R1 ≤5 cm tumor (arm B); RT (55.8 Gy)/CT for R0/R1 >5 cm tumor (arm C); or neoadjuvant RT (45 Gy)/CT plus delayed surgery, CT, and postoperative boost to 10.8 Gy R0 <5 mm margins/R1 or 19.8 Gy for R2/unresected tumors (arm D). RESULTS: One hundred ninety-three eligible patients had 24 LRs (arm B 1/15 [6.7%], arm C 7/65 [10.8%], arm D 16/113 [14.2%]) at median time to LR of 1.1 years (range, 0.11-5.27). Of 95 eligible for delayed surgery after neoadjuvant therapy, 89 (93.7%) achieved R0/R1 margins. Overall LC after RT were as follows: R0, 106 of 109 (97%); R1, 51 of 60 (85%); and R2/unresectable, 2 of 6 (33%). LR predictors include extent of delayed resection (P <.001), imaging response before delayed surgery (P < .001), histologic subtype (P <.001), and no RT (P = .046). The 5-year event-free survival was significantly lower (P = .0003) for patients unable to undergo R0/R1 resection. CONCLUSIONS: Risk-based treatment for young patients with high-grade NRSTS treated on ARST0332 produced very high LC, particularly after R0 resection (97%), despite lower-than-standard RT doses. Neoadjuvant CT/RT enabled delayed R0/R1 resection in most patients and is preferred over adjuvant therapy due to the lower RT dose delivered.
PURPOSE: The ARST0332 trial for pediatric and young adults with nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) used risk-based treatment including primary resection with lower-than-standard radiation doses to optimize local control (LC) while minimizing long-term toxicity in those requiring radiation therapy (RT). RT for high-grade NRSTS was based on extent of resection (R0: negative margins, R1: microscopic margins, R2/U: gross disease/unresectable); those with >5 cm tumors received chemotherapy (CT; ifosfamide/doxorubicin). This analysis evaluates LC for patients assigned to RT and prognostic factors associated with local recurrence (LR). METHODS AND MATERIALS: Patients aged <30 years with high-grade NRSTS received RT (55.8 Gy) for R1 ≤5 cm tumor (arm B); RT (55.8 Gy)/CT for R0/R1 >5 cm tumor (arm C); or neoadjuvant RT (45 Gy)/CT plus delayed surgery, CT, and postoperative boost to 10.8 Gy R0 <5 mm margins/R1 or 19.8 Gy for R2/unresected tumors (arm D). RESULTS: One hundred ninety-three eligible patients had 24 LRs (arm B 1/15 [6.7%], arm C 7/65 [10.8%], arm D 16/113 [14.2%]) at median time to LR of 1.1 years (range, 0.11-5.27). Of 95 eligible for delayed surgery after neoadjuvant therapy, 89 (93.7%) achieved R0/R1 margins. Overall LC after RT were as follows: R0, 106 of 109 (97%); R1, 51 of 60 (85%); and R2/unresectable, 2 of 6 (33%). LR predictors include extent of delayed resection (P <.001), imaging response before delayed surgery (P < .001), histologic subtype (P <.001), and no RT (P = .046). The 5-year event-free survival was significantly lower (P = .0003) for patients unable to undergo R0/R1 resection. CONCLUSIONS: Risk-based treatment for young patients with high-grade NRSTS treated on ARST0332 produced very high LC, particularly after R0 resection (97%), despite lower-than-standard RT doses. Neoadjuvant CT/RT enabled delayed R0/R1 resection in most patients and is preferred over adjuvant therapy due to the lower RT dose delivered.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Dian Wang; Qiang Zhang; Burton L Eisenberg; John M Kane; X Allen Li; David Lucas; Ivy A Petersen; Thomas F DeLaney; Carolyn R Freeman; Steven E Finkelstein; Ying J Hitchcock; Manpreet Bedi; Anurag K Singh; George Dundas; David G Kirsch Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: Avani D Rao; Qinyu Chen; Lynn Million; Sheri L Spunt; Thomas J Fitzgerald; Chen Hu; Sandesh S Rao; Fran Laurie; Sandy Kessel; Karen Morano; Matthew M Ladra; Stephanie A Terezakis Journal: Int J Radiat Oncol Biol Phys Date: 2018-09-10 Impact factor: 7.038
Authors: M L Blakely; W W Spurbeck; A S Pappo; C B Pratt; C Rodriguez-Galindo; V M Santana; T E Merchant; M Prichard; B N Rao Journal: J Pediatr Surg Date: 1999-05 Impact factor: 2.545
Authors: C B Pratt; A S Pappo; P Gieser; J J Jenkins; A Salzbergdagger; J Neff; B Rao; D Green; P Thomas; R Marcus; D Parham; H Maurer Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Thomas F DeLaney; Ira J Spiro; Herman D Suit; Mark C Gebhardt; Francis J Hornicek; Henry J Mankin; Andrew L Rosenberg; Daniel I Rosenthal; Fariba Miryousefi; Marcus Ancukiewicz; David C Harmon Journal: Int J Radiat Oncol Biol Phys Date: 2003-07-15 Impact factor: 7.038
Authors: Kenneth R Gundle; Lisa Kafchinski; Sanjay Gupta; Anthony M Griffin; Brendan C Dickson; Peter W Chung; Charles N Catton; Brian O'Sullivan; Jay S Wunder; Peter C Ferguson Journal: J Clin Oncol Date: 2018-01-18 Impact factor: 44.544
Authors: A Ferrari; G L De Salvo; B Brennan; M M van Noesel; A De Paoli; M Casanova; N Francotte; A Kelsey; R Alaggio; O Oberlin; M Carli; M Ben-Arush; C Bergeron; J H M Merks; M Jenney; M C Stevens; G Bisogno; D Orbach Journal: Ann Oncol Date: 2014-12-08 Impact factor: 32.976
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17